AngioDynamics Launches MORPHEUS CT PICC INSERTION KIT Nationwide.QUEENSBURY, N.Y. -- AngioDynamics, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ANGO ANGO Algemene Nederlandse Gehandicapten Organisatie (Dutch: Equal Opportunities for Persons with Disabilities) ) today announced the nationwide launch of the MORPHEUS(R) CT PICC PICC Peripherally-inserted central catheter Critical care An IV catheter inserted in the superior vena cava for long-term infusion of bolus or continuous delivery of therapeutics or TPN–drugs, fluids, nutrients, chemotherapy. Cf Catheter. INSERTION KIT. Use of the INSERTION KIT allows the Company's proprietary peripherally inserted central catheter A peripherally inserted central catheter- (PICC or PIC line) is a form of intravenous access that can be used for a prolonged period of time, e.g. for long chemotherapy regimens, extended antibiotic therapy or total parenteral nutrition. (PICC) to be inserted at a patient's bedside, instead of in the interventional radiology suite at the hospital, which is the current practice. The INSERTION KIT, which has been specifically designed for interventional radiologists, nurse practitioners, physician assistants and radiology technicians who perform the placement of PICCs, is now available for immediate distribution throughout the United States. "The MORPHEUS CT PICC INSERTION KIT reflects our continued dedication and commitment to expanding our product offerings to meet the needs of our customers and their patients, and we are very excited that this kit is now available for sale across the Unites States," commented Eamonn P. Hobbs, president and chief executive officer of AngioDynamics. "Our new product offering includes everything needed to safely insert the MORPHEUS CT PICC at the patient's bedside, thus reducing physician time and improving patient comfort. Complementing our current MORPHEUS CT PICC basic and full kits, the INSERTION KIT provides customers a choice of where to perform the procedure," Mr. Hobbs added. The MORPHEUS CT PICC is used for short and long-term peripheral access to the central venous system for intravenous therapy and power injections of contrast media. It features the dual durometer catheter shaft made of Durathane(TM), a biocompatible biocompatible /bio·com·pat·i·ble/ (-kom-pat´i-b'l) being harmonious with life; not having toxic or injurious effects on biological function. and durable material that offers increased stiffness for ease of placement while also providing patient comfort. The use of Durathane also helps simplify site care since the material can be cleaned with either iodine or alcohol. About AngioDynamics AngioDynamics, Inc. (www.angiodynamics.com) is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease Peripheral Vascular Disease Definition Peripheral vascular disease is a narrowing of blood vessels that restricts blood flow. It mostly occurs in the legs, but is sometimes seen in the arms. . AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company's diverse product line includes angiographic products, dialysis products, vascular access products, PTA PTA or parent-teacher association: see parent education. products, oncology products, thrombolytic thrombolytic /throm·bo·lyt·ic/ (throm?bo-lit´ik) dissolving or splitting up a thrombus, or an agent that so acts. thrombolytic 1. dissolving or splitting up a thrombus. 2. an agent that dissolves or splits up a thrombus. products and venous products. The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. or other regulatory agencies, results of pending or future clinical trials, results of pending patent litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. , overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended May 28, 2005, may affect the actual results achieved by the Company. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion